Leiting Jennifer L, Cloyd Jordan M, Ahmed Ahmed, Fournier Keith, Lee Andrew J, Dessureault Sophie, Felder Seth, Veerapong Jula, Baumgartner Joel M, Clarke Callisia, Mogal Harveshp, Staley Charles A, Zaidi Mohammad Y, Patel Sameer H, Ahmad Syed A, Hendrix Ryan J, Lambert Laura, Abbott Daniel E, Pokrzywa Courtney, Raoof Mustafa, LaRocca Christopher J, Johnston Fabian M, Greer Jonathan, Grotz Travis E
Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55901, United States.
Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
World J Gastrointest Oncol. 2020 Jul 15;12(7):756-767. doi: 10.4251/wjgo.v12.i7.756.
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis can be performed in two ways: Open or closed abdominal technique.
To evaluate the impact of HIPEC method on post-operative and long-term survival outcomes.
Patients undergoing CRS with HIPEC from 2000-2017 were identified in the United States HIPEC collaborative database. Post-operative, recurrence, and overall survival outcomes were compared between those who received open closed HIPEC.
Of the 1812 patients undergoing curative-intent CRS and HIPEC, 372 (21%) patients underwent open HIPEC and 1440 (79%) underwent closed HIPEC. There was no difference in re-operation or severe complications between the two groups. Closed HIPEC had higher rates of 90-d readmission while open HIPEC had a higher rate of 90-d mortalities. On multi-variable analysis, closed HIPEC technique was not a significant predictor for overall survival (hazards ratio: 0.75, 95% confidence interval: 0.51-1.10, = 0.14) or recurrence-free survival (hazards ratio: 1.39, 95% confidence interval: 1.00-1.93, = 0.05) in the entire cohort. These findings remained consistent in the appendiceal and the colorectal subgroups.
In this multi-institutional analysis, the HIPEC method was not independently associated with relevant post-operative or long-term outcomes. HIPEC technique may be left to the discretion of the operating surgeon.
腹膜癌的细胞减灭术(CRS)联合热灌注化疗(HIPEC)可通过两种方式进行:开放或闭合腹部技术。
评估热灌注化疗方法对术后及长期生存结果的影响。
在美国热灌注化疗协作数据库中识别出2000年至2017年接受CRS联合HIPEC的患者。比较接受开放或闭合热灌注化疗患者的术后、复发及总生存结果。
在1812例接受根治性CRS和HIPEC的患者中,372例(21%)接受开放热灌注化疗,1440例(79%)接受闭合热灌注化疗。两组在再次手术或严重并发症方面无差异。闭合热灌注化疗的90天再入院率较高,而开放热灌注化疗的90天死亡率较高。在多变量分析中,闭合热灌注化疗技术在整个队列中并非总生存(风险比:0.75,95%置信区间:0.51 - 1.10,P = 0.14)或无复发生存(风险比:1.39,95%置信区间:1.00 - 1.93,P = 0.05)的显著预测因素。这些发现在阑尾和结直肠亚组中保持一致。
在这项多机构分析中,热灌注化疗方法与相关术后或长期结果无独立关联。热灌注化疗技术可由手术医生自行决定。